The markets on September 11, 2018 opened up. BSE Sensex is trading at 37,869.63, down by 52.54 points and the Nifty is trading at 11,423.10, down by 15.00 points.

Global pharmaceutical company, Zydus Cadila has received the tentative approval from USFDA for Sitagliptin. 

On 11^th September, 2018, UltraTech Cement announced its decision to join EP100, thereby committing to double its energy productivity. The company has set a target to lower its carbon intensity by 25 per cent by 2021, as notified in a press release. Thus, this decision reestablishes their commitment toward making considerable improvements in energy productivity, thereby paving the way for sustainable business growth.

Overall volumes in futures & options currently stand at 81.92 lakh contracts with a turnover of Rs. 8,01,491.11 crore.

Overall volumes in futures & options currently stand at 81.92 lakh contracts with a turnover of Rs. 8,01,491.11 crore.

Going ahead, the levels of 11,390, followed by 11,320, are likely to act as immediate support levels. On the way up, the index has strong resistance in the zone of 11,550-11,600 and the index needs to convincingly pass through this resistance zone if it has to gain some real strength in the near term.  Stocks in news: Sun Pharmaceuticals, Jaiprakash Associates, Container Corporation of India, Manali Petrochemicals, Yes Bank and NMDC.

Markets in India are expected to open with modest losses as cues from Asian peers are mixed.  The SGX Nifty suggests that the Nifty could open lower by 20 points around the level of 11,466.

There are various ways in which an investor defines ‘long-term’. Different investors define long-term in different ways. Read on to find why long-term is more than 10 years.

The following stocks hit 52-week high on September 10, 2018 – Axis Bank Limited, GlaxoSmithKline Pharmaceuticals Limited, JSW Steel Limited, LGB Forge Limited and Lincoln Pharmaceuticals Limited. These stocks might be in action in tomorrow’s trading session.

The company's arm has acquired a Israel-based early stage research company focusing on development of drug candidates for Ophthalmology segment.